Christopher F Reilly

Title: The Innovations of Christopher F. Reilly

Introduction

Christopher F. Reilly is a notable inventor based in Wilmslow, GB. He has made significant contributions to the field of medical science, particularly in the area of vascular health. His work focuses on developing innovative solutions to combat vascular restenosis, a common complication following various cardiovascular procedures.

Latest Patents

Reilly holds a patent for his invention titled "AT-2 antagonist inhibition of vascular restenosis." This patent describes novel disubstituted 6-aminoquinazolinones that serve as angiotensin-II receptor (subtype 2) antagonists. These compounds can be used alone or in combination with heparin to suppress vascular stenosis, which often occurs during the development of atherosclerosis and after procedures such as arterial angioplasty, stent placement, bypass surgery, heart transplantation, or endarterectomy.

Career Highlights

Christopher F. Reilly is associated with Merck & Co., Inc., a leading global healthcare company. His work at Merck has allowed him to focus on innovative research aimed at improving patient outcomes in cardiovascular health. His dedication to advancing medical science is evident through his patent and ongoing research efforts.

Collaborations

Reilly has collaborated with esteemed colleagues, including Stephen E. DeLaszlo and Robert G. Johnson. These partnerships have contributed to the development of groundbreaking medical solutions and have enhanced the impact of his work in the field.

Conclusion

Christopher F. Reilly's contributions to medical innovation, particularly in vascular health, highlight the importance of research and collaboration in advancing healthcare solutions. His patent for AT-2 antagonists represents a significant step forward in addressing vascular restenosis, showcasing his commitment to improving patient care.